Skip to main content

Table 1 Baseline characteristics of participants

From: Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial

Subject Age Gender Education, years Medication MMSE ADAS-Cog APOE genotype Amyloid PET
LD_01 59 M 9 Donepezil 5 mg 21 19 e3/e4 Positive
LD_02 65 F 12 Donepezil 10 mg 26 19 e3/e3 Positive
LD_03 63 F 12 Donepezil 10 mg 25 16 e4/e4 Positive
HD_01 60 M 18 Donepezil 10 mg 18 20 e3/e4 Positive
HD_02 76 F 12 Donepezil 7.5 mg 17 27 e3/e3 Positive
HD_03 50 F 14 Rivastigmine 9.5 mg/24 h 14 29 e3/e3 Positive
HD_04 66 F 6 Memantine 10 mg, donepezil 10 mg 24 19 e3/e4 Positive
HD_05 53 F 16 Donepezil 10 mg 24 13 e3/e3 Positive
HD_06 73 M 12 Rivastigmine 9.5 mg/24 h 21 29 e4/e4 Positive
  1. LD, low dose; HD, high dose; AChE-I, acetylcholine esterase inhibitor; MMSE, Mini-Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale